773 results on '"Bendahl, Pär-Ola"'
Search Results
2. Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial
3. Serum immuno-oncology markers carry independent prognostic information in patients with newly diagnosed metastatic breast cancer, from a prospective observational study
4. The implementation of a noninvasive lymph node staging (NILS) preoperative prediction model is cost effective in primary breast cancer
5. PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients
6. RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer
7. Preoperative prediction of nodal status using clinical data and artificial intelligence derived mammogram features enabling abstention of sentinel lymph node biopsy in breast cancer.
8. Health-related quality of life by type of breast surgery in women with primary breast cancer: prospective longitudinal cohort study.
9. Gene expression in metastatic breast cancer—patterns in primary tumors and metastatic tissue with prognostic potential
10. Gene expression in metastatic breast cancer – patterns with prognostic potential in primary tumors and metastatic tissue
11. High CYP27A1 expression is a biomarker of favorable prognosis in premenopausal patients with estrogen receptor positive primary breast cancer
12. Expression of epithelial-mesenchymal transition-related markers and phenotypes during breast cancer progression
13. Noninvasive Staging of Lymph Node Status in Breast Cancer Using Machine Learning: External Validation and Further Model Development
14. Prediction of Tamoxifen Benefit in Premenopausal Breast Cancer Patients Evaluated by Three Methods for Determination of Hormone Receptor Status
15. Protocol for the T-REX-trial: tailored regional external beam radiotherapy in clinically node-negative breast cancer patients with 1-2 sentinel node macrometastases – an open, multicentre, randomised non-inferiority phase 3 trial
16. Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer
17. The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast
18. The effect of statin treatment on intratumoral cholesterol levels and LDL receptor expression: a window-of-opportunity breast cancer trial
19. Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up
20. Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer - data from the randomized SBII:2 trial
21. Longitudinal Assessment of Circulating Tumor Cells and Outcome in Small Cell Lung Cancer: A Sub-Study of RASTEN—A Randomized Trial with Low Molecular Weight Heparin
22. Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer
23. Statin use, HMGCR expression, and breast cancer survival – The Malmö Diet and Cancer Study
24. The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence
25. Supplementary Figure S2 from G Protein–Coupled Estrogen Receptor Is Apoptotic and Correlates with Increased Distant Disease-Free Survival of Estrogen Receptor–Positive Breast Cancer Patients
26. Figure S1 from Prediction of Lymph Node Metastasis in Breast Cancer by Gene Expression and Clinicopathological Models: Development and Validation within a Population-Based Cohort
27. Supplementary Methods, Figures 3-5 from Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma
28. Supplementary Fig. S1 from Global Transcriptional Changes Following Statin Treatment in Breast Cancer
29. Supplementary Table 4 from Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma
30. Supplementary Table 3 from Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma
31. Supplementary Figure 2 from Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma
32. Supplementary Table 2 from Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma
33. Supplementary Figure 1 from Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma
34. Supplementary Table 1 from Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma
35. Supplementary Figure Legends 53 from Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma
36. Appendix S1 from Prediction of Lymph Node Metastasis in Breast Cancer by Gene Expression and Clinicopathological Models: Development and Validation within a Population-Based Cohort
37. Supplementary Table S1 from G Protein–Coupled Estrogen Receptor Is Apoptotic and Correlates with Increased Distant Disease-Free Survival of Estrogen Receptor–Positive Breast Cancer Patients
38. Supplementary Data from Estrogen Receptor β Expression Is Associated with Tamoxifen Response in ERα-Negative Breast Carcinoma
39. Data from Nuclear Janus-Activated Kinase 2/Nuclear Factor 1-C2 Suppresses Tumorigenesis and Epithelial-to-Mesenchymal Transition by Repressing Forkhead Box F1
40. Supplementary Movie 1 from Nuclear Janus-Activated Kinase 2/Nuclear Factor 1-C2 Suppresses Tumorigenesis and Epithelial-to-Mesenchymal Transition by Repressing Forkhead Box F1
41. Supplementary Table from Nuclear Janus-Activated Kinase 2/Nuclear Factor 1-C2 Suppresses Tumorigenesis and Epithelial-to-Mesenchymal Transition by Repressing Forkhead Box F1
42. Supplementary Table Legend from Nuclear Janus-Activated Kinase 2/Nuclear Factor 1-C2 Suppresses Tumorigenesis and Epithelial-to-Mesenchymal Transition by Repressing Forkhead Box F1
43. Supplementary Figure Legend from Nuclear Janus-Activated Kinase 2/Nuclear Factor 1-C2 Suppresses Tumorigenesis and Epithelial-to-Mesenchymal Transition by Repressing Forkhead Box F1
44. Supplementary Movie 2 from Nuclear Janus-Activated Kinase 2/Nuclear Factor 1-C2 Suppresses Tumorigenesis and Epithelial-to-Mesenchymal Transition by Repressing Forkhead Box F1
45. Supplementary Figure 1 from Nuclear Janus-Activated Kinase 2/Nuclear Factor 1-C2 Suppresses Tumorigenesis and Epithelial-to-Mesenchymal Transition by Repressing Forkhead Box F1
46. Supplementary Methods from Nuclear Janus-Activated Kinase 2/Nuclear Factor 1-C2 Suppresses Tumorigenesis and Epithelial-to-Mesenchymal Transition by Repressing Forkhead Box F1
47. Supplementary Movie Legends 1-2 from Nuclear Janus-Activated Kinase 2/Nuclear Factor 1-C2 Suppresses Tumorigenesis and Epithelial-to-Mesenchymal Transition by Repressing Forkhead Box F1
48. Low levels of WRAP53 predict decreased efficacy of radiotherapy and are prognostic for local recurrence and death from breast cancer: a long‐term follow‐up of the SweBCG91RT randomized trial
49. Retrospective Validation Study of an Artificial Neural Network-Based Preoperative Decision-Support Tool for Noninvasive Lymph Node Staging (NILS) in Women with Primary Breast Cancer (ISRCTN14341750)
50. Abstract P1-09-06: Save the breast after neoadjuvant therapy – identifying radiological and tumor related factors of importance for breast conserving surgery after neoadjuvant chemotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.